A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy

Francis J. Giles*, Roberto Rodriguez, Daniel Weisdorf, John R. Wingard, Paul J. Martin, Thomas R. Fleming, Stuart L. Goldberg, Elias J. Anaissie, Brian J. Bolwell, Nelson J. Chao, Thomas C. Shea, Mark M. Brunvand, William Vaughan, Finn Petersen, Mark Schubert, Hillard M. Lazarus, Richard T. Maziarz, Margarida Silverman, Roy A. Beveridge, Rebecca RedmanJanis G. Pulliam, Patricia Devitt-Risse, Henry J. Fuchs, David D. Hurd

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Fingerprint

Dive into the research topics of 'A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science